Scarica l'app Stockscreener
0.1937
3.73%
-0.0075
Dopo l'orario di chiusura:
.20
0.0063
+3.25%
Precedente Chiudi:
$0.2012
Aprire:
$0.1987
Volume 24 ore:
1.99M
Relative Volume:
1.56
Capitalizzazione di mercato:
$2.26M
Reddito:
-
Utile/perdita netta:
$-23.66M
Rapporto P/E:
-0.014
EPS:
-13.84
Flusso di cassa netto:
$-10.14M
1 W Prestazione:
-13.06%
1M Prestazione:
-47.78%
6M Prestazione:
-85.56%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.1864
$0.207
Intervallo di 1 settimana:
$0.1815
$0.2386
Portata 52W:
$0.1615
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
Nome
Tnf Pharmaceuticals Inc
Settore
Industria
Telefono
856-848-8698
Indirizzo
1185 AVENUE OF THE AMERICAS, NEW YORK
Confronta TNFA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNFA
Tnf Pharmaceuticals Inc
|
0.1937 | 2.26M | 0 | -23.66M | -10.14M | -13.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Tnf Pharmaceuticals Inc Borsa (TNFA) Ultime notizie
A new trading data show TNF Pharmaceuticals Inc (TNFA) is showing positive returns. - Sete News
TNF Pharmaceuticals Inc Inc. (TNFA) Price Performance: A Guide to Financial Ratios - investchronicle.com
Is TNF Pharmaceuticals Inc (TNFA) worth investing in despite its overvalued state? - uspostnews.com
Gaining Ground: TNF Pharmaceuticals Inc (TNFA) Closes Lower at 0.25, Down -9.00 - DWinneX
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TNF Pharmaceuticals Inc (NASDAQ:TNFA) Is Looking Good Over The Long Term, Dropped Nearly -46.01% Over A Month. – Marketing Sentinel - Marketing Sentinel
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ - GlobeNewswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
TNF Pharmaceuticals Inc (TNFA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish - MSN
TNF and Renova Health use AI to identify patients for GLP-1 treatments - Yahoo Finance
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish By Stocktwits - Investing.com India
TNF Pharmaceuticals uses AI to refine patient selection for trials By Investing.com - Investing.com South Africa
TNF Pharmaceuticals uses AI to refine patient selection for trials - Investing.com
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development - Business Wire
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
TNF Pharmaceuticals Inc Inc. (TNFA) Price Performance Over the Years: A Comparative Study - investchronicle.com
Market Recap Check: Sangamo Therapeutics Inc (SGMO)’s Positive Finish at 0.71, Up/Down 2.96 - DWinneX
Gaining Ground: TNF Pharmaceuticals Inc (TNFA) Closes Lower at 0.18, Down -25.44 - DWinneX
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Benzinga
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025 - The Joplin Globe
Corebridge Financial Inc. Trims Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
TNF Pharmaceuticals, Inc. SEC 10-K Report - TradingView
TNF Pharmaceuticals Inc: Navigating Market Fluctuations with a 0.75M Market Cap - investchronicle.com
TNFA stock touches 52-week low at $0.32 amid market challenges - Investing.com Canada
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Now Is A Good Time To Buy TNF Pharmaceuticals Inc (NASDAQ: TNFA) - Marketing Sentinel
A Key Driver Transforming the TNF Alpha Inhibitors Market in 2025: The Prevalence Of Inflammatory Diseases ... - WhaTech
Contrasting Myriad Genetics (NASDAQ:MYGN) & TNF Pharmaceuticals (NASDAQ:TNFA) - Defense World
TNF Pharmaceuticals faces Nasdaq delisting over price - Investing.com
TNF Pharmaceuticals faces Nasdaq delisting over price By Investing.com - Investing.com India
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent - Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Sarcopenia Market Expected to Experience Major Growth by 2034, - openPR.com
TNF Pharmaceuticals presents isomyosamine data - Yahoo Finance
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - Joplin Globe
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call - TipRanks
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - BioSpace
Raythera describes new TNF-α modulators - BioWorld Online
RILY’s current quarter earnings: What analysts forecast? - US Post News
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Are T1 Energy Inc (FREY) shares a good deal now? - US Post News
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - BioSpace
Can This First-Ever Oral TNF Inhibitor Disrupt a $40 Billion Market? Phase 2b Trial Begins - StockTitan
Tnf Pharmaceuticals Inc Azioni (TNFA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):